Comparative healthcare costs in patients with metastatic melanoma in the USA

Melanoma Research

Volumn 25, Issue 4, 2015, Pages 312-320

  Chang, Chun Lan ^a   Schabert, Vernon F ^a   Munakata, Julie ^a   Donga, Prina ^a   Abhyankar, Sarang ^b   Reyes, Carolina M ^b   Yim, Yeun Mi ^b  

^a IQVIA   (United States)

^b GENENTECH INC   (United States)

Author keywords

healthcare utilization and costs; ipilimumab; metastatic melanoma; real world; US commercially insured population; vemurafenib

Indexed keywords

DACARBAZINE; IPILIMUMAB; PACLITAXEL; TEMOZOLOMIDE; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; SULFONAMIDE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA BASE; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG PACKAGING; DRUG SAFETY; ENTEROCOLITIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART ARREST; HEPATITIS; HUMAN; HYPOTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; METASTATIC MELANOMA; MIDDLE AGED; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES; ANALOGS AND DERIVATIVES; ECONOMICS; HEALTH INSURANCE; IMMUNOTHERAPY; MELANOMA; MOLECULARLY TARGETED THERAPY; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DACARBAZINE; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOTHERAPY; INDOLES; MALE; MANAGED CARE PROGRAMS; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PACLITAXEL; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; UNITED STATES;

EID: 84936941639     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000159     Document Type: Article

References (39)

1. National Institute of Cancer. SEER stat fact sheets: melanoma of the skin. Melanoma skin-SEER stat fact sheets. Available at: http://seer.cancer.gov/statfacts/html/melan.htm [Accessed 24 June 2014].
2. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001; 93:678-683.
3. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007; 109:455-464.
4. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009; 9:587-595.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
6. Velho TR. Metastatic melanoma-a review of current and future drugs. Drugs Context 2012; 2012:212242-212242.
7. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 2007; 33:665-680.
8. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
9. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 (Suppl 1):S11-S14.
10. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
11. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47:1476-1483.
12. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9:59-64.
13. Wiernik PH, Einzig AI. Taxol in malignant melanoma. J Natl Cancer Inst Monogr 1993; 15:185-187.
14. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 2004; 14:63-66.
15. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002; 25:283-286.
16. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, et al. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol 2009; 32:509-514.
17. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
18. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur J Cancer 2013; 49 (Suppl 3).
19. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
20. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S, Hemminki K. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9:3362-3368.
21. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012; 48:94-100.
22. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30:2522-2529.
23. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15:323-332.
24. U.S. Food and Drug Administration. Pembrolizumab. 2014. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm412861.htm [Accessed 22 September 2014].
25. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55:490-500.
26. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100:630-641.
27. Hillner BE, Kirkwood JM, Agarwala SS. Burden of illness associated with metastatic melanoma: an audit of 100 consecutive referral center cases. Cancer 2001; 91:1814-1821.
28. Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy 2009; 7:31-41.
29. Reyes C, DaCosta Byfield S, Linke R, Satram-Hoang S, Teitelbaum AH. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. Melanoma Res 2013; 23:159-166.
30. Genentech Inc. Zelboraf Package Insert. Available at: http://www.gene.com/download/pdf/zelboraf-prescribing.pdf [Accessed 1 October 2014].
31. Bristol-Myers Squibb Company. Yervoy Package Insert. Available at: http://packageinserts.bms.com/pi/piyervoy.pdf. [Accessed 1 October 2014].
32. Teva Parenteral Medicines Inc. Dacarbazine Package Insert. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid =26e91082-7698-4680-beab-07c47802f0f9 [Accessed 1 October 2014].
33. Merck & Co. Inc. Temodar Package Insert. Available at: http://www.merck.com/product/usa/picirculars/t/temodarcapsules/temodarpi.pdf [Accessed 1 October 2014].
34. Bristol-Myers Squibb Company. Taxol Package Insert. Available at: http://packageinserts.bms.com/pi/pi-taxol.pdf [Accessed 1 October 2014].
35. Graubard BI, Korn EL. Predictive margins with survey data. Biometrics 1999; 55:652-659.
36. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005; 6:93-109.
37. National Comprehensive Cancer Network. National Comprehensive Cancer Network-Melanoma Volume V4. National Comprehensive Cancer Network; 2014. Available at: http://www.nccn.org/professionals/physician-gls/f-guide lines.asp#site.
38. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-1030.
39. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144.